Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Rising Oil Majors Help Offset Sinking Glaxo

Wed, 03rd Feb 2021 16:58

(Alliance News) - It was a mixed day in London on Wednesday, with the FTSE 100 fizzling in afternoon trade as pharma giant GlaxoSmithKline took a dive.

The FTSE 100 index closed off 8.83 points or 0.1%, at 6,507.82, despite gaining as much as 0.9% in morning trading.

The FTSE 250 ended up 62.23 points, or 0.3%, at 20,752.44. The AIM All-Share closed up 9.99 points, or 0.8%, at 1,198.95.

The Cboe UK 100 ended down 0.2% at 646.49, the Cboe UK 250 closed up 0.2% at 18,286.10, and the Cboe Small Companies ended up 1.0% at 12,325.51.

In Paris, the CAC 40 ended marginally lower, while the DAX 30 in Frankfurt advanced 0.7%.

Glaxo lost 6.3%, the worst performer in the blue chip index, after it said adjusted earnings per share fell in 2020, and it expects further decline in the year ahead.

Revenue for 2020 rose 1.0% to GBP34.10 billion from GBP33.75 billion in 2019, with pretax profit growing 12% to GBP6.97 billion from GBP6.22 billion. Consensus had seen Glaxo posting revenue of GBP34.02 billion.

Adjusted earnings per share fell 6% to 115.9 pence, or a 4% decline at constant exchange rates. For 2021, Glaxo expects a "mid to high-single digit percent" decline in adjusted earnings per share at constant currencies.

SpreadEx analyst Connor Campbell noted this is higher than the 3% drop expected by analysts, explaining the drop in share price.

The firm expects healthcare systems and consumer trends will approach normality in the second half of this year, with turnover expected to show flat to low-single digit growth for the Pharmaceuticals and Vaccines businesses and low to mid-single digit growth for Consumer Healthcare.

The firm added it is on track for separation into new standalone Biopharma and Consumer Healthcare companies in 2022.

Separately, Glaxo said it will collaborate with German biopharmaceutical company CureVac to develop next generation mRNA vaccines for Covid-19, with the potential to address multiple emerging variants in one vaccine.

Helping to combat the GSK drop, and keeping the FTSE 100 flat, was London's oil majors rising on swelling oil prices.

Brent oil was quoted at USD58.64 a barrel at the London close, up from USD57.58 at the close Tuesday.

ThinkMarkets analyst Fawad Razaqzada said: "Following three weeks of consolidation, crude oil prices have surged further higher this week. At the time of writing, they were holding near their weekly highs amid expectations of rebounding demand while ongoing OPEC+ supply cuts are also helping to keep the market not too far from being balanced.

"But the rally is unlikely to last too long, in my view. Normal travel is unlikely to start for some time yet, which means the potential upside could be limited from here as the rebound in demand is going to be slow. Also, as prices rise and demand returns, the OPEC will be easing its supply cuts, while shale oil is likely to ramp up production at the same time. Therefore, I can’t see oil prices climbing significantly higher from these levels, although for the time being the path of least resistance remains to the upside."

IG Chief Market Analyst Chris Beauchamp added: "Both BP and Shell have staged a rally today, as the market digests the former's earnings and prepares for the latter. Shell is likely to say broadly the same things as its FTSE 100 peer, namely that it is putting an annus horribilis firmly behind it, and with demand still rising and oil prices on the up it looks like oil majors around the globe have good reason to be cautiously confident."

On Tuesday, BP reported a swing to an annual loss following a tumultuous year in which the global oil and gas industry faced severe challenges.

For 2020, BP swung to a replacement cost loss of USD18.10 billion from an RC profit of USD3.52 billion in 2019 on revenue of USD183.50 billion, down 35% from USD282.62 billion.

For Shell tomorrow, company-compiled consensus sees adjusted earnings at USD5.05 billion for 2020, down 69% on the USD16.46 billion reported for 2019. Adjusted earnings per share are also seen falling 69%, to USD0.64 from USD2.04 the year before.

Analysts consensus has the company reporting lower cash flow from operating activities for 2020. This is expected to be down at USD34.24 billion from USD42.18 billion a year prior.

Shell 'A' shares advanced 0.9% Wednesday, while the 'B' shares rose 1.3%. BP gained 1.3%.

Also in the green, Vodafone ended the FTSE 100's best performer, up 5.9%, after the telecommunications firm said it returned to organic service revenue growth in its third-quarter, helped by a much stronger showing in Germany.

Total revenue in the quarter ended December 31 fell 4.7% to EUR11.20 billion from EUR11.75 billion a year earlier. The organic figure - which strips out the effects M&A activity and currency movements - was 0.4%.

Vodafone generates the bulk of its cash from service revenue, which includes monthly access charges, airtime usage and roaming. In the third quarter ended December, service revenue rose 0.4% on an organic basis. The organic service revenue figure is one that is closely eyed by analysts.

In Germany alone, service revenue rose 1.0% year-on-year on both an organic and reported basis to EUR2.91 billion.

Aviva ended up 3.7% after Morgan Stanley upgraded the blue-chip insurer to Overweight from Equal Weight.

Taylor Wimpey and Persimmon gained 0.9% and 1.5% respectively after Barclays upgraded both UK housebuilders to Overweight from Equal Weight.

Schroders added 1.0% after UBS upped the wealth manager to Buy from Neutral.

The pound was quoted at USD1.3651 at the London equities close, up from USD1.3644 at the close Tuesday.

In the US, Wall Street was muted at the London equities close. The DJIA was 0.2% lower, while both the S&P 500 index and the Nasdaq Composite were up 0.1%.

IG's Beauchamp believes the afternoon data in the US has left investors buying into a 'good news is bad news' thesis.

He said: "The February rally in equities has been deflated somewhat this afternoon, at least in the US, where the bounce from Friday's lows has encountered its first real challenge after breezing higher for 48 hours. Undoubtedly some of the blame will get pinned on today's ADP and ISM numbers, both of which came in stronger than anticipated, and in the case of the payroll report much stronger, with the argument being better data will strengthen the hands of the fiscal hawks on Capitol Hill and give them more firepower in their attempts to water down any Biden stimulus package."

The ISM Services PMI rose to 58.7 in January from 57.7 in December, while US private sector employment increased by 174,000 jobs in January, recovering from a downwardly revised 78,000 jobs in December. The latest figure beat market forecasts, cited by FXStreet, for an increase of 49,000 jobs.

The euro stood at USD1.2022 at the European equities close, down from USD1.2029 late Tuesday. Against the yen, the dollar was trading at JPY105.05, unchanged from late Tuesday.

Gold was quoted at USD1,835.90 an ounce at the London equities close, lower against USD1,837.20 late Tuesday.

In the economic calendar on Thursday there is a UK Markit construction PMI reading at 0930 GMT, followed by eurozone retail sales at 1000 GMT and US initial jobless claims at 1330 GMT.

The focus, however, will remain on the the Bank of England's latest monetary policy decision, alongside the release of the Monetary Policy Committee meeting minutes and the quarterly Monetary Policy Report, at midday on Thursday. A press conference will follow at 1300 GMT.

Analysts largely expect the central bank to stand pat on policy this week despite a recent surge in coronavirus cases, with focus around the debate over negative interest rates.

The Bank Rate, the UK's key interest rate, currently lies at a record low 0.10%, cut to that level back in March last year as the pandemic first hit.

A busy UK corporate calendar on Thursday is headlined by oil major Shell's annual results, alongside annual results from consumer goods giant Unilever, half-year results from housebuilder Barratt Developments and a third quarter update from BT Group.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Aug 2023 11:56

LONDON MARKET MIDDAY: Stocks down over US rate hike worries

(Alliance News) - Stock prices in Europe were lower at midday on Thursday, after the US Federal Reserve warned that a further interest rate hike may be on the cards.

Read more
17 Aug 2023 08:53

LONDON MARKET OPEN: Stocks fall further after hawkish US Fed minutes

(Alliance News) - Stock prices in London opened in the red on Thursday, amid renewed concerns about further US interest rate increases.

Read more
13 Aug 2023 14:06

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

(Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian

Read more
10 Aug 2023 15:46

UK dividends calendar - next 7 days

Friday 11 August 
Blackrock Latin American Investment Trust PLCdividend payment date
Caffyns PLCdividend payment date
CMC Markets PLCdividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Next 15 Group PLCdividend payment date
Ninety One PLC and Ltddividend payment date
Schroder European Real Estate Investment Trust PLCdividend payment date
Sportech PLCspecial dividend payment date
Telecom Plus PLCdividend payment date
Triad Group PLCdividend payment date
Wincanton PLCdividend payment date
Monday 14 August 
Mountview Estates PLCdividend payment date
Tuesday 15 August 
Tatton Asset Management PLCdividend payment date
Wednesday 16 August 
Murray International Trust PLCdividend payment date
Shoe Zone PLCdividend payment date
Thursday 17 August 
4imprint Group PLCex-dividend payment date
abrdn PLCex-dividend payment date
abrdn Property Income Trust Ltdex-dividend payment date
Anglo American PLCex-dividend payment date
Baillie Gifford UK Growth Trust PLCex-dividend payment date
Berkeley Group Holdings PLCex-dividend payment date
BlackRock Sustainable American Income Trust PLCex-dividend payment date
Bridgepoint Group PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
ConvaTec Group PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
GSK PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
Hiscox Ltdex-dividend payment date
Impact Healthcare REIT PLCex-dividend payment date
Imperial Brands PLCex-dividend payment date
Investec PLC and Ltdex-dividend payment date
iomart Group PLCex-dividend payment date
Keller Group PLCex-dividend payment date
Lancashire Holdings Ltdex-dividend payment date
London Stock Exchange Group PLCex-dividend payment date
Montanaro European Smaller Cos Trust PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Rotork PLCex-dividend payment date
Sabre Insurance Group PLCex-dividend payment date
Schroders PLCex-dividend payment date
Sirius Real Estate Ltddividend payment date
Tritax EuroBox PLCex-dividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
7 Aug 2023 08:12

PRESS: Inflexion among firms looking to buy Haleon's nicotine business

(Alliance News) - Sky News reported on Sunday that Inflexion Private Equity Partners is among suitors for Haleon PLC's Nicotinell anti-smoking aid.

Read more
3 Aug 2023 16:31

GSK Nigeria calls an end to its business, to return cash

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods.

Read more
2 Aug 2023 20:45

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

Read more
2 Aug 2023 15:14

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 14:28

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 10:41

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

Read more
2 Aug 2023 08:23

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

Read more
31 Jul 2023 19:42

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

Read more
31 Jul 2023 12:21

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

Read more
31 Jul 2023 09:16

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
26 Jul 2023 11:06

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.